Using molecular profiles to predict the drug response is of practical importance in precision medicine and have been extensively studied. Due to the complexity of molecular information, the existing methods couldn't capture enough information and their prediction performances are not satisfying. In this study, we propose a method called DIMDRP (double iteration method for drug response prediction) which improves a lot in the prediction accuracy. DIMDRP integrates several important molecular information including miRNA expression, drug chemical structure, target interaction, drug-target interaction and cell line-drug response, and constructs a heterogeneous network. Then an improved information flow iteration algorithm is used to calculate association scores of cell line-drug responses, and we prioritize the cell lines for each query drug. The cross-validation experiments show that the average area under curve (AUC) of DIMDRP is as high as 0.8953, and two other measurement metrics are applied to assess the performance. When compared to other approaches, our method shows a significant advantage for all metrics. We also consider the specific tissue condition into our competition from a practical aspect. Last, a case is studied to predict novel cell line-drug responses, some of which can be evidenced by previous experiments.
I. INTRODUCTION
The high complicated mechanism of cancers makes it difficult to find effective medicines for personal treatment, and different individuals respond differently to the same medicine. Conventional methods of discovering new drug responses are always based on many biological experiments that cost lots of money and time. With the great development in biological technologies, more and more molecular information about human genome, transcriptome and proteome has been accumulated, and it provides researchers a novel way to study the association between drugs and cell lines. Now there exists a trend to conduct the drug response prediction analysis with these accessible data [1] . Recently, plenty of large-scale studies have been conducted to collect the corresponding biological data. Two famous of them are Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) which provide public access The associate editor coordinating the review of this manuscript and approving it for publication was Xiangtao Li . to the genomic data of more than 1000 cancer cell lines and their drug responses to 266 anticancer drugs [2] , [3] . The massive data from these studies are available for researchers which accelerates researches on drug response prediction methods.
Hence many computational methods have been proposed which help find new medicine and may enable us to get a more profound insight into cancer pathogenesis. Fang et al. introduced a three-step quantile regression forest approach that screens important features of cell lines using a random forest procedure and their experiments showed a good performance on the CCLE database [4] . Wei et al. proposed a cell line-drug complex network model by combining similarity information of drugs and cell lines with the drug response information from the above databases [5] . By hypothesizing that the gene expression changes caused by using different drugs could reflect the drug interaction effects, Cheng et al. integrated genomic properties and developed a novel machine learning-based prediction method to predict drug-drug interactions [6] . However, the above methods mainly focus on the molecular information within the cell line and drug when predicting the drug response, and it is hard to further improve the prediction accuracy.
To break through the limitation, researchers began to concentrate on some missing information such as drug chemical structure, cell lines' molecular profiles and so on. By using the genetic and molecular signatures from the CCLE database, Costello et al. developed a synthesize prediction framework with two supervised learning methods [7] . Liu et al. integrated the cell line similarity network and drug similarity network, and viewed the prediction task as a recommender system. The improvement of capturing global network structure contributed to better prediction performance [8] . By incorporating additional information such as the drug response similarity, Zhang et al. utilized a weighted collaborative filtering method to predict the drug response. Their results showed that the added information could improve the prediction accuracy [9] . Guan et al. proposed a weighted graph regularized matrix factorization method to infer the cell line-drug association, and the method was based on the drug fingerprint descriptors, gene expression profile and the known drug response, which could predict most drug responses correctly [10] . On the basis of previous works, Zhang et al. constructed a heterogeneous network of cell line and drug, and conducted an information flow method HNMDRP (a heterogeneous network method for drug response prediction) to capture more useful information [11] .
The above methods can accurately predict the responses for some drugs. However, they didn't work effectively with the traditional small-molecule drugs. According to the previous study [12] , protein-protein interaction (PPI) and drug-target association information could be used to improve the performance of drug response prediction. Stanfield et al. [13] constructed a heterogeneous network including cell line mutation information, drug responses and gene profiles from GDSC. It achieved the goal of predicting the missing connection between drug and cell line through a random walk with restart algorithm. Their experiments [13] showed that gene mutation information and the hide topology information of the network could help predict drug responses. Despite the outstand prediction performance, Stanfield's method neglected the fact that similarity information of genes is also useful to drug response prediction.
To overcome the limitations of the above methods, we integrated the similarity information of drugs, cell lines and proteins, and proposed a method called DIMDRP (double iteration method for drug response prediction). DIMDRP combines cell line miRNA profile, drug chemical structure information and PPI interaction information as well as associations between them. Different from HNMDRP [11] , our method switches the information flow direction of the heterogeneous network and uses a double iterative updating algorithm to obtain the cell line-drug interaction scores. For each query drug, we prioritize the candidate cell lines according to their scores which reflect the drug response intensity. We compared the performances of our method with other four state-of-the-art methods in a series of leave-oneout cross-validation (LOOCV) experiments. The experiment results showed that the ROC curves of our method lie above others for most cases, which implied that DIMDRP generally outperformed the other methods. When considering the recall rate in top-K predicted sensitive cell lines, DIMDRP still performed best in general. We used DIMDRP to detect novel cell line-drug responses, and found that most of our predicted novel responses have been verified by previous literature.
II. MATERIAL AND METHODS

A. EXPERIMENTAL DATA
In this study, our experimental data were based on the benchmark database GDSC and CCLE. The GDSC database supplies the IC50 response values between 266 drugs and 1065 cell lines which can be used to measure the drug response statues. CCLE database provides the miRNA expression profiles of 1457 cell lines. To ensure the clarity of biological meaning, we conduct a filter procedure. We only kept the cell lines from GDSC which have common names in the miRNA expression profiles from CCLE, and the drugs that have associations with the remained cell lines. Finally, there were 188 drugs and 626 cell lines left for the following experiments. The data of cell lines and drugs include information about drug response profile, drug structure similarity profile, and cell line miRNA expression profile. Besides, we also downloaded the associations between the 188 drugs and 243 target genes from the GDSC database. To construct the relationship between the target genes, we downloaded 4850628 PPIs data from the STRING database and extract 396419 interactions which connected with 243 target genes [14] . Based on the above data, we calculated the similarity of drugs, cell lines and target genes, and constructed a heterogeneous network as shown in Fig 1(A) .
To calculate the similarity between two vectors X and Y, we first compute their Pearson correlation coefficient P cc according to Equation (1).
where X (and Y) denoted the mean value of X (and Y).
To evaluate the significance of that X is similar to Y, we use t-test to obtained the p-value.
1) CELL LINE SIMILARITY NETWORK
We downloaded the normalized miRNA expression profile of 626 cell lines from GDSC. The profile consisted of 626 feature vectors of 737 dimensions, and the Pearson correlation coefficient of two vectors was used as the similarity score of the corresponding cell lines [15] . According to [11] , we selected the cell line similarity pairs whose P cc values ranked in the top 50% and p-values were lower than 0.01, and used the selected pairs to construct a cell line similarity network with their P cc values representing the cell line similarity scores. The cell line similarity network was represented by a 626 × 626 cell line similarity matrix SIM cc whose element was the similarity score of cell lines.
2) CELL LINE-DRUG INTERACTION NETWORK
From the GDSC databases, we download 95946 drug responses with log-normalized IC50 values. We used the threshold provided in Iorio's work [16] to determine the response status. A drug response was labelled as sensitive or resistant according to whether the IC50 value is lower or higher than the threshold, and it resulted in 33372 sensitive, 62574 resistant and 21742 unknown interactions between 626 cell lines and 188 drugs. A 626 × 188 cell line-drug interaction matrix A cd was constructed based on these data and we used the matrix A cd to represent the cell line-drug interaction network.
3) DRUG SIMILARITY NETWORK
The chemical structure profile consisted of 188 drugs of 14000 dimensions, which was downloaded from Pub-Chem. The chemical structure features included the 1-D structure features and 2-D structure features. The 1-D structure features consisted of the compositional molecular properties such as the acid number and base number. The 2-D structure features consisted of multi properties which could reflect the cell line's molecular topology information such as Xlogp value and Kappa indices. Here we also used the Pearson correlation coefficient to measure the similarity between two different drugs and obtained a 188 × 188 drug similarity matrix SIM dd . The SIM dd was used to represent the drug similarity network.
4) DRUG-TARGET INTERACTION NETWORK
We fist construct an initial drug-target interaction network based on the drug-target interactions between 188 drugs and 243 target genes from GDSC. Then we downloaded the PPIs interactions data from the STRING database, dropped the proteins whose corresponding genes didn't have any association with the proteins corresponding the target genes, and there were 3040 proteins left. The PPI of the left 3040 proteins was recorded by a matrix M ppi . Finally, we extended the number of target genes from 243 to 3040, and obtained a 188×3040 drug-target interaction matrix A dt , which was used to represent the drug-target interaction network.
5) TARGET SIMILARITY NETWORK
We calculated the similarity of target genes based on the information of M ppi and the gene expression profile. To avoid the effect of noises in M ppi , we set the elements smaller than 0.4 with 0. Finally, there were 396419 elements in M ppi whose values are not zero. Similar to [11] , we calculated the normalized matrix W ppi from M ppi according to Equation (2).
where D ppi (i) denoted the sum of i-th row elements in M ppi , The elements of W ppi denote the interaction scores between target genes. From the gene expression profile, we calculated P cc of each pair of the 3040 target genes based on their miRNA expression vectors, and obtained a 3040 × 3040 matrix W corr recording the correlational scores.
Similar to [14] , we obtained a 3040 × 3040 target similarity matrix SIM tt based on W ppi and W corr according to Equaion (3) .
We used the target similarity matrix SIM tt to represent the target similarity network.
B. DIMDRP
We integrated the cell line similarity network, the cell linedrug interaction network, the drug similarity network, the drug-target interaction network and the target similarity network into a heterogeneous network. Based on the heterogeneous network, with an idea of switching the information flow direction and a double iterative updating algorithm, we computed the cell line-drug interaction scores to predict the drug responses as shown in Fig 1(B-C) . The proposed method was called DIMDRP (double iteration method for drug response prediction).
The heterogeneous network was denoted by G (C, D, T, E), which included three types of nodes: cell line nodes, drug nodes and target gene nodes. C, D and T denoted the node sets of cell line, drug and target gene respectively. E denoted the set of weighted edges between the above nodes. The weights of edges in G were determined by SIM cc , SIM dd , SIM tt , A dt and A cd . To predict the cell line-drug responses, we used a double iteration method based on information flow in the heterogeneous network and the iteration method equations are as follows.
where the matrix A 0 cd represented the initial cell line-drug interaction matrix, SIM cc , SIM dd and SIM tt denoted the similarity matrices of cell lines, drugs and targets respectively. α 1 and α 2 were the decay factors whose values ranged from 0 to 1. Firstly, we calculated Equation (4) which was viewed as a propagation algorithm and obtained the k + 1 step cell line-drug interaction matrix. After this, we needed to reverse A cd according to Equation (5) . And through Equation (6), we integrated the drug similarity information and the target similarity information into the cell line-drug network. Then Equation (7) reversed A dc and enable the next updating. After k iterations, and when the difference value between A k+1 cd and A k cd lower than a threshold T h , the matrix A k+1 cd could be viewed as the final score matrix. What's more, we needed to conduct a normalization procedure to make sure that the values can converge [17] . The normalization formula was defined in Equation (8):
where W denoted SIM dd × A k dt × SIM tt × A k T dt or SIM cc and the Norm was the normalization matrix.
C. VALIDATION AND EVALUATION EXPERIMENTS
In our study, we conducted the leave-one-out crossvalidation [18] experiments to evaluate the prediction performance of DIMDRP. First, we chose a query drug and obtained the set of cell lines which were sensitive to the drug. Then we took turns to select a cell line-drug interaction as the test case. In each turn, we deleted the edge in the heterogeneous network corresponding to the selected sensitive cell line-drug interaction, and obtained a new heterogeneous network. Based on the new heterogeneous network, we run drug-response prediction algorithms to calculate all the cell line-drug interaction scores with a larger score indicating that the corresponding cell line-drug pair is more likely to be sensitive. In this study, we used three measurement metrics to evaluate the prediction performance. The first was the area under the receiver operating characteristic curve (AUC). We plotted the receiver operating characteristic (ROC) curve to assess the predictive performance with the true positive rates and the false positive rates at different cutoff points. And we conducted quantitative analysis by calculating AUC. The larger AUC value indicated better prediction performance. The second was the area under the precision-recall curve (AUPR). AUPR measurement could reflect the prediction accuracy better under imbalanced condition. We plotted the precisionrecall (PR) curve and calculated AUPR. The third was top-K recall number. The top-K recall number is the number of real sensitive cell lines in K cell lines whose prediction scores are at top, which could reflect the ability of detecting important responses.
III. RESULTS
A. PARAMETER SETTING
There were three parameters in our method: α 1 , α 2 and T h . α 1 and α 2 were the decay factors that controlled the information assignment from the original cell line-drug interactions to the updated cell line-drug interactions. T h was utilized to decide when the iteration procedure will stop, and it was generally set a small value. In our experiments, we set T h = 10 −4 . Fig 2 showed the average AUCs of DIMDRP with different α 1 and α 2 . The red line in Fig 2 showed that when α 2 = 0.1, the average AUCs changed with different α 1 , and achieved the maximum when α 1 = 0.7. The blue line in Fig 2 showed that when α 1 = 0.7, the average AUCs changed with different α 2 , and reached the best when α 2 = 0.1. It was easy to see that the performance of DIMDRP was greatly affected by the α 2 . In the following experiments, we set α 1 = 0.7 and α 2 = 0.1.
B. METHODS COMPARISON
To assess the prediction performance of our method DIMDRP, we compared DIMDRP with four state-of-the-art drug response prediction methods: HNMDRP [11], Zhang's method [19] , Stanfield's method [13] and SVMDRP [20] . For the four methods, we set the parameters for each method as suggested by each literature. Then we compared the predict performance of the five methods over all 188 drugs by LOOCV experiments according to three measurement metrics: AUC, AUPR and top-K recall number. Fig 3(A-D) compared the methods in the metric AUC on four drugs CEP-701, NVP-BHG712, PD-0332991 and CP466722. The ROC curve of DIMDRP was clearly above the other four methods. For example, for the drug CEP-701, the AUC value of DIMDRP was 26.2% and 9.8% higher than HNMDRP and SVMDRP respectively. A boxplot was used to compare the AUCs of five methods on 188 drugs as shown in Fig 3(E) . DIMDRP achieved good performance for most drugs: AUC > 0.8887 for 50% drugs and AUC > 0.8507 for 75% drugs. It was obvious that our method generally outperformed the other four in AUC. The average AUCs of DIMDRP, HNMDRP, Zhang's method, Stanfield's method and SVMDRP on 188 drugs were 0.8953, 0.7797, 0.7639, 0.6947 and 0.7416 respectively, which were shown in Fig  3(F) . The highest AUC of DIMDRP was 0.9984 which was achieved on the pyrrolotriazine drug named BMS-754807. Fig 4(A-B) compared the methods according to their AUPRs on drugs CGP-60474 and VX-11e. The performance of all methods declined greatly compared with their AUC performance, which showed that the prediction capability of all methods got worse under imbalanced condition. Fig 4(C) showed a boxplot of their AUPRs on 188 drugs. Even the number of sensitive response (33372) and resistant response (62574) was a huge imbalance, DIMDRP still showed a nice prediction performance, and its AUPR distribution was AUPR > 0.5647 for 50% drugs and AUPR > 0.3011 for 75% drugs. The average AUPRs of DIMDRP, HNMDRP, Zhang's method, Stanfield's method and SVMDRP were 0.5741, 0.4755, 0.4628, 0.4317 and 0.4691 respectively, which were shown in Fig 4(D) . The highest AUPR of DIMDRP was 0.9978 with the macrolide drug named (5Z)-7-Oxozeaenol.
Another measurement to assess the performance was the top-K retrieved number of sensitive cell lines. Fig 5 showed the top 10, 20, 50 and 100 retrieved numbers of sensitive cell lines on 3 commonly used clinical drugs Dabrafenib, MLN4924 and Afatinib, and the results illustrated again that DIMDRP outperformed the other methods.
The above results demonstrated that DIMDRP could effectively prioritized the cell lines which was really sensitive to the query drug. To explore the effect of the target similarity information, drug similarity information and cell line similarity information, we also performed three self-comparison experiments that neglected each of the three information respectively. Fig 6(A) showed that the average AUC of DIMDRP dropped down to 0.8419, 0.7956 and 0.8163 when the target similarity information, drug similarity information and cell line similarity information were removed from the heterozygous network respectively.
We also tested the shuffling experiments with the different types of edges in the network deleted or added randomly. Based on the shuffled heterogeneous network, the average AUCs of 188 drugs were also calculated and the results were shown in Fig 6(B) . In the shuffling experiments, all average AUCs under different conditions were around 0.5, which demonstrated that all types of information in the heterozygous network did help improve the predict power of DIMDRP.
Compared with Stanfield's method, DIMDRP's predict performance improved a lot since our method integrated target gene similarity information, miRNA expression information and drug chemical structure information. Meanwhile the information flow-based method used by DIMDRP could capture the topology structure information more accurately, which was also a factor contributing to the good prediction performance of DIMDRP.
C. TISSUE SPECIFIC CONDITIONS
In practice, the cancer clinical treatments are always devised for the specific origin tissues of the cancer. It is important to consider the tissue specific conditions when evaluating the performance of drug response prediction methods [21] . Fig 7(A) showed the distribution of most tissue types of the cancer cell lines in our experiments. We tested the methods on the three major tissue types lung_NSC, glioma and colorectal.
For each type of the three, we only kept the drugs that possess at least 5 sensitive connections with the cell lines of the issue type and constructed a specific tissue heterogeneous network. We compared DIMDRP with the other four methods using the specific tissue data. The experimental results were shown in Fig 7(B) . The average AUCs on the lung_NSC, glioma and colorectal tissue data were 0.7919, 0.7465 and 0.7513 for DIMDRP, were 0.7124, 0.6348, 0.6575 for HNM-DRP, were 0.6942, 0.6171, 0.6420 for Zhang's method, were 0.6730, 0.6315, 0.6118 for Stanfield's method, and were 0.6879, 0.6584, 0.6294 for SVMDRP respectively. Fig 7(B) showed that DIMDRP still outperformed the other four methods in the tissue specific conditions. Compared with the average AUCs on the pan-cancer data (including all cancer cell lines), the AUCs of all methods declined with only one issue type of cell lines, which may be caused by smaller sample of issue specific data.
D. NOVEL DRUG RESPONSE PREDICTION
We also used DIMDRP to predict novel cell line-drug responses. For each drug, we ranked all the cell lines in descending order according to their drug response predict scores. After deleting the cell lines with known responses to the drug, we selected the top 20 cell lines as our novel drug response recommendations. Table 1 presented the top six cell lines with predicted novel response to several drugs. The cell lines were NCI-H82, A549, HS-578-T, CAL-33, MOLM-16 and HSC-3, which were evidenced by previous literature [22] - [27] .
IV. CONCLUSION AND DISCUSSION
In this study, we proposed DIMDRP to predict drug responses which was based on a heterogeneous network integrating the drug similarity information, target similarity information and interaction information between cell line, drug and target. To evaluate the effectiveness of our method, we conducted LOOCV experiments on the entire database and tissue-specific database downloaded from GDSC and CCLE. We compared our method with other four art-ofthe-state methods, and the results showed that DIMDRP generally outperformed the other methods. Especially, when compared with HNMDRP, DIMDRP improved greatly in prediction performance, which mainly owes to the addition of the cell line miRNA similarity information. Meanwhile, the improved double iterative information flow algorithm with switching flowing direction in the heterozygous network used by DIMDRP could help to balance the assigning of the diverse biological data resource in the network, which may result in a more accurate prediction of DIMDRP. With respect to the novel response prediction, DIMDRP also showed its good prediction power, and some of the predicted novel drug responses had been confirmed by previous literature.
The extensive experiments showed that our method could be applied to predict drug response effectively.
DIMDRP could not only be used to predict the drug responses, but also be used to predict miRNA-disease association and small molecular-miRNA association [28] , [29] with some minor modifications. In future, inspired by a previous work [30] , we would develop drug response prediction from for a single drug prediction to a combination of several drugs, which would make the prediction more useful in clinical application. Since the integration of cell line miRNA expression information, drug chemical structure information and drug response information with the PPI network helps DIMDRP improve the drug response prediction accuracy, we believe that the performance could be further improved by admitting extra information, such as other kinds of cell lines gene expression profiles, the cell line functional annotations, drug function similarity information and so on.
